Your session is about to expire
← Back to Search
Camidanlumab Tesirine for Hodgkin's Lymphoma
Study Summary
This trial will test a new drug, Camidanlumab Tesirine, for people with HL who haven't responded to other treatments. The goal is to see if it's effective and safe.
- Hodgkin's Lymphoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 117 Patients • NCT04052997Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this a pioneering exploration of the subject matter?
"Camidanlumab Tesirine has been under clinical investigation since 2018, when it was first trialled by ADC Therapeutics S.A.. Following the successful completion of Phase 1 in which 95 patients were enrolled, approval for a drug-based intervention was granted. Currently there are 3 live trials being conducted across 11 nations and 30 cities worldwide."
How many participants is this trial accommodating?
"This research has ceased to recruit participants. It was posted in September of 2019 and last modified in November 2022. If you are interested, there are currently 1723 studies for lymphoma patients seeking volunteers and 3 trials specifically recruiting Camidanlumab Tesirine candidates."
Is Camidanlumab Tesirine officially sanctioned by the FDA?
"Our team assigned Camidanlumab Tesirine a score of 2 because it has undergone Phase 2 trials, demonstrating some safety but no efficacy yet."
Has Camidanlumab Tesirine been the subject of any further research?
"Currently, a mere 3 medical trials are actively researching the effects of Camidanlumab Tesirine with none having yet reached phase 3. Durham North carolina is hosting some of these studies while 88 other sites have opened their doors to patient recruitment for this medication."
Is enrollment currently open for this clinical trial?
"This clinical trial has ended its recruitment phase. Initially posted on September 13th 2019, the protocol was last updated November 11th 2022. Presently, there are 1723 studies recruiting for lymphoma and 3 trials actively searching for Camidanlumab Tesirine patients."
Share this study with friends
Copy Link
Messenger